Format

Send to

Choose Destination
J Diabetes Complications. 2014 Sep-Oct;28(5):742-9. doi: 10.1016/j.jdiacomp.2014.04.003. Epub 2014 Apr 16.

Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.

Author information

1
Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA. Electronic address: juliorosenstock@dallasdiabetes.com.
2
Tulane University Health Sciences Center, New Orleans, LA, USA.
3
Sanofi Deutschland GmbH, Frankfurt, Germany.
4
Sanofi, Paris, France.
5
Department of Statistics, University of Auckland, Auckland, New Zealand.
6
Oregon Health & Science University, Portland, OR, USA.

Abstract

AIMS:

This analysis evaluated HbA1c-adjusted hypoglycemia risk with glargine versus neutral protamine Hagedorn (NPH) over a 5-year study in patients with Type 2 diabetes mellitus (T2DM). Clinical significance was assessed using number needed to harm (NNH) to demonstrate the risk of one additional patient experiencing at least one hypoglycemic event.

METHODS:

Individual patient-level data for symptomatic documented hypoglycemia and HbA1c values from a 5-year randomized study comparing once-daily glargine (n=513) with twice-daily NPH (n=504) were analyzed. Symptomatic hypoglycemia was categorized according to concurrent self-monitoring blood glucose levels and need for assistance. Hypoglycemic events per patient-year as a function of HbA1c were fitted by negative binomial regression using treatment and HbA1c at endpoint as independent variables. An estimate of NNH was derived from logistic regression models.

RESULTS:

The cumulative number of symptomatic hypoglycemia events was consistently lower with glargine compared with NPH over 5years. Compared with twice-daily NPH, once-daily glargine treatment resulted in significantly lower adjusted odds ratios (OR) for all daytime hypoglycemia (OR 0.74; p=0.030) and any severe event (OR 0.64; p=0.035), representing a 26% and 36% reduction in the odds of daytime and severe hypoglycemia, respectively. Our model predicts that, if 25 patients were treated with NPH instead of glargine, then one additional patient would experience at least one severe hypoglycemic event.

CONCLUSIONS:

This analysis of long-term insulin treatment confirms findings from short-term studies and demonstrates that glargine provides sustained, clinically meaningful reductions in risk of hypoglycemia compared with NPH in patients with T2DM.

KEYWORDS:

Clinical diabetes; Clinical science and care; Glargine; Hypoglycemia; NPH

PMID:
24856612
PMCID:
PMC4802045
DOI:
10.1016/j.jdiacomp.2014.04.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center